ShiftPixy, Inc. (NASDAQ: PIXY) is “One to Watch”

The rise of the sharing economy model and gig economy, empowered by mobile IT and big data, has rapidly transformed an antiquated labor market, where the average independent worker often ended up dependent on temp agencies (which aggregated this labor pool) in order to find employment. However, this evolution of the labor market has come with legal pitfalls, stemming from companies wanting to categorize workers as independent contractors, instead of as employees, and thereby avoiding benefit entitlements like unemployment insurance and minimum-wage protections that are stipulated under state labor laws. This is a problem to which sector innovator ShiftPixy, Inc. (NASDAQ: PIXY) believes it has the answer, in the form of a new hybridized model where workers are treated as full-time employees of ShiftPixy, who are then lent out to clients on an independent contractor basis.

According to recent analysis by TurboTax owner Intuit (NASDAQ: INTU), which has been witnessing the growth of the gig economy via its own earnings, the broader freelancer labor market now makes up 34 percent of the workforce and is on track to hit 43 percent by 2020 (http://dtn.fm/9kKC4). While we won’t see U.S. Labor Department data until next year on the freelance labor market, the Intuit research project conducted with Emergent Research indicates there are around four million quintessential gig workers, and that the number is likely to grow to 7.7 million by 2020.

Needless to say, ShiftPixy’s disruptive new hybrid worker classification model is perfectly timed to capture this projected growth, resolving the complications that have led sector juggernauts like Uber to face repeated litigation. Last year, Uber reached a landmark $100 million settlement to two class action lawsuits in California and Massachusetts over the status of its drivers as independent contractors (http://dtn.fm/KS0hb).

GrubHub (NYSE: GRUB) also faced litigation last year over these same issues with its delivery drivers (http://dtn.fm/4txoV),  and the specter of such litigation still looms large for the industry, despite recent victories like the one in Florida (http://dtn.fm/Prip3), where an appeals court upheld the state governor’s decision that Uber drivers are independent contractors. Uber’s $68.5 billion valuation, backed by strategic investors like General Motors (NYSE:GM) and Microsoft (NASDAQ: MSFT), was recently pegged at just $50 billion by secondary shareholders (http://dtn.fm/7HSaW). This decline has opened the door to up and comers like Lyft, which has backing from the likes of Icahn Enterprises (NASDAQ: IEP) and KKR & Co. (NYSE: KKR), as well as Chinese companies Alibaba (NYSE: BABA) and Tencent (OTC: TCEHY).

The recently launched ShiftPixy mobile app (http://dtn.fm/Evv2v) allows the company’s employees, which it calls “shifters,” to access and select shifts in real-time from the pool of broadcasted open shifts on the ShiftPixy Shifter Network. This offers shifters an all new level of free agency as workers, while streamlining the overall process for business operators who have open shifts they need to fill by giving them real-time access to a wealth of fully-vetted and available shifter candidates. Moreover, this immensely powerful recruiting and scheduling platform tracks and communicates with fixed and flex staff, and it does so within an environment designed from the ground up to be compliance-driven. Accurate and simple pay management from the ShiftPixy platform, which adapts to most time and attendance systems, allows business operators to handle reporting and compliance without failure while enabling the fine tuning of escalating worker compensation costs.

ShiftPixy is basically the best of both worlds. On the one hand, you have unprecedented freedom for shift workers who get to be classed as full-time employees, and, on the other, you have a pre-verified ecosystem of candidates for worksite employers, so long as they are part of the ShiftPixy universe. ShiftPixy’s co-founder and CEO, Scott Absher, noted at the time of the app launch that the automation provided by ShiftPixy’s platform not only makes the worker onboarding process extremely simple and paperless; it also acts as a secure personal gateway for shifters to manage all of their employment data.

Perhaps signifying how ShiftPixy’s human capital management (HCM) platform is rebooting the temp worker and developing into a truly 21st century hub for workers and business operators alike, the company recently announced the opening of its first regional office in New York City’s historic Grand Central Station (http://dtn.fm/8sRSI). This move plants an unambiguous ShiftPixy flag on the 56 million-plus Northeast region, which is one of the mostly densely populated and important regions to consider when studying the rapidly expanding contingent workforce. Seen as a crucial market by management, New York City’s always-on, 24-hour nature, as well as the size of its leisure and hospitality industries, are inescapable catalysts behind the thriving local gig economy.

ShiftPixy’s uptake will most likely be driven by the sheer ease of use for business operators, who can utilize the platform to easily navigate complex regulatory mandates while minimizing the often daunting administrative burdens associated with shift work staffing in general. ShiftPixy’s comprehensive HCM ecosystem could easily become the standard solution for dealing with regulatory requirements like paid time off laws and Affordable Care Act stipulations, and it has drawn considerable attention from sector analysts since the company’s $12 million IPO in June (http://dtn.fm/aC8tI). Currently trading around $3.71 with a $105 million market cap, ShiftPixy made a good showing at the influential Drexel Hamilton 2017 TMT Conference in early September, where Absher was able to really demonstrate his three decades-plus of organizational development, capital development and employment industry expertise. The de-risked compliance environment will continue to differentiate Irvine, California-headquartered ShiftPixy from other gig economy operators, as the company continues to provide a foundationally pitch-perfect blend of insurance products, regulatory compliance services and proprietary human administration tools to a labor market whose future is still largely up in the air.

You might say that there is a new sheriff in town and that ShiftPixy’s quest to free the contingent worker is a noble crusade, but there is no need for such characterizations when it is clearly a well-timed and heartfelt Uberization aimed at transforming the temp staffing agency and PEO (professional employer organization) space in a way that is meaningful for often marginalized workers. ShiftPixy could become a real boon for unemployed, under-employed, and part-time workers. That potential, in and of itself, is an abundant investment proposal, as it represents significant good will and proactive public relations/marketing of the ShiftPixy brand, which appears to be a genuine solution to the problem of ensuring equitable employment practices in the gig economy.

Human Resources in an app that lets workers find shift gigs which fit into their schedules could be a real game changer for what is a large and growing population of gig economy workers.

For more information, visit the company’s website at www.ShiftPixy.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Simplifies Mobile Payments with O2O Commerce Marketplace

A recent Global Mobile Money Report by Nielsen (http://dtn.fm/7rflL) shows that almost half of Chinese consumers will likely use a mobile device to make payments in restaurants, bars and retail stores—a much higher number than among consumers in the United States and Europe. Cashing in on China’s cashless trend and having recently upgraded its mobile payments capability, Moxian, Inc. (NASDAQ: MOXC) is doing business at the confluence of online retail and brick-and-mortar establishments, operating an online platform that utilizes social media to drive business to small and medium-sized enterprises (SMEs).

An article further discussing this reads: “In early 2017, the company announced the launch of a new version of its Moxian User App and Business App (New Version Apps) that feature built-in UnionPay payment modules. This follows the company’s strategic partnership with Beijing Chinaums, a subsidiary of China UnionPay, in December 2016. This seamless integration of Moxian’s proprietary virtual currency engine and UnionPay’s powerful payment gateway will allow users (merchants and shoppers) of the New Version Apps to process payments through UnionPay’s payment gateway, which also supports payments from Alipay and WeChat Pay. The UnionPay payment gateway also meshes seamlessly with Moxian’s MO-Coin and MO-Point system, which rewards customers who use and process payments with the New Version Apps. The Moxian Software Machine also tracks customer behavior, which in turn allows Moxian to provide the participating merchants with complete and detailed analytic data and tools. Merchants on the Moxian Marketplace can study the behavior of their customers and respond with precise targeted marketing campaigns.”

To view the full article, visit http://dtn.fm/Dub3f

About Moxian, Inc.

Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the Company can be found at www.moxian.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

India Globalization Capital, Inc. (NYSE: IGC) Preparing to Bring Cannabis Combo Therapy for Alzheimer’s Disease to Trials

• Four drug candidates in the pipeline
• Potential sales of Alzheimer’s drugs run to billions
• Hyalolex heading for clinical trials

India Globalization Capital, Inc. (NYSE MKT: IGC) is racing ahead with its preparation of medical trials for four drug candidates that treat a variety of debilitating conditions. At the head of the line is Hyalolex, aimed at reducing the buildup of amyloid β-peptide (Aβ) plaques on neurons in the brain, a process that causes the crippling cognitive complaint known as Alzheimer’s disease.

Alzheimer’s afflicts more than five million Americans, and, so far, no effective cure for this form of dementia has been found. However, the FDA has approved five medications to treat its symptoms. IGC is hoping to make Hyalolex the sixth. The drug works through a molecular pathway that allows low doses of THC to bind to Aβ plaques and so prevent them from aggregating on neurons. IGC has entered into a definitive license agreement (http://dtn.fm/7Xsmp) with the University of South Florida (USF), which makes IGC the exclusive licensee of the USF-developed technology that is the subject of a U.S. patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” If approved, Hyalolex could go some way to reducing the costs of treating Alzheimer’s, estimated to reach $259 billion in 2017. It should also bring IGC’s market cap in line with peer valuations that range in the hundreds of millions.

Alzheimer’s has the unwelcome distinction of being number five on the list of America’s five most deleterious diseases, after heart disease, cancer, chronic lower respiratory conditions and strokes, according to the Centers for Disease Control and Prevention (CDC). Every minute, someone new develops the condition, which takes its toll not just on those afflicted but on caregivers. The Alzheimer’s Association says that ‘35% of caregivers for people with Alzheimer’s or another dementia report that their health has gotten worse due to care responsibilities, compared to 19% of caregivers for older people without dementia”. The economic cost is also staggering and, if no cure or palliative is found soon, is expected to exceed $1 trillion by 2050.

With such high stakes, IGC’s pioneering therapy has become vitally important. Its mechanism of action uses the psychotropic component of cannabis, Δ9-tetrahydrocannabinol (THC), to inhibit the enzyme acetylcholinesterase (AChE) and prevent the aggregation of AChE-induced amyloid β-peptide (Aβ), which is the key pathological marker of Alzheimer’s disease.

Current treatments authorized for sale to the public by the U.S. Food and Drug Administration (FDA) for Alzheimer’s include donepezil, approved in 1996; galantamine (2001); rivastigmine (2000); memantine (2003); and a combination of donepezil and memantine, approved in 2014. Sales of donepezil (Aricept) reached $3.5 billion in 2009, the year before its generics were allowed market entry. Sales of rivastigmine (Exelon) have been in the hundreds of millions, exceeding $1.0 billion in 2011, and sales of memantine (Namenda) continue annually above $1.0 billion. According to Mordor Intelligence, “the global Alzheimer’s’ disease market… due to drug patent expirations in 2017 and many generics entering the market… is expected to see a declination… by the year 2017. (On the other hand), the market is anticipated to grow driven by… last-stage pipeline drugs”. They might have added “like Hyalolex.”

IGC’s pipeline also includes Natrinol, a natural substitute for Marinol, or synthetic THC, aimed at relieving nausea and vomiting while increasing appetite in patients with AIDS and cancer; Caesafin, which uses combination therapy to alleviate seizures in dogs and cats; and Serosapse, which addresses several end-points in Parkinson’s disease, including rapid eye movement (REM) sleep disorder, anxiety and dyskinesia.

For more information, visit the company’s website at www.IGCInc.us

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Moxian, Inc. (NASDAQ: MOXC) Shareholders to Vote on Seven Directors at Annual Meeting on September 29 in Beijing

• Director nominees include Liu Shu Juan, CEO of Shewn International Group and financial controller of Shanghai Shewn Wine Co.
• Moxian is expected to formalize joint venture agreement with Shewn International Group by end of September 2017
• Joint ventures are part of Moxian’s new strategy to enter major markets in China more quickly and at lower cost

Moxian, Inc. (NASDAQ: MOXC) will nominate seven directors to its board for shareholders at its annual meeting on September 29, 2017, in Beijing, China (http://dtn.fm/y8lBO). Among the seven is Liu Shu Juan, chief executive officer of Shewn International Group, Inc. and financial controller of Shanghai Shewn Co., Ltd., the company’s primary operator in China.

Liu has been a Moxian board member since August 2017. Moxian has an agreement of understanding with Shewn International Group, Inc., expected to be finalized by the end of September 2017, for a joint venture as part of a new marketing strategy for Moxian. The Shanghai-based company plans a series of joint ventures to enable it to penetrate key markets in China more quickly and at a lower cost. James Mengdong Tan, president and chief executive officer of Moxian, told Crystal Equity Research that he has some opportunities for 30-40 companies in the pipeline for future joint ventures.

Moxian is an integrated platform operator focused on processing digital payments and converting its Moxian+ Merchant and Moxian+ User apps to paid. It has a module on its Moxian+ Merchant platform for UnionPay, the dominant digital payment processor in China. That module makes joint ventures with Moxian attractive to other businesses.

Crystal Equity Research endorses the new joint venture strategy, citing its planned effectiveness and cost cutting in Moxian’s entry into new markets. Crystal Equity has projected that Moxian will achieve sales of $2.3 million by FY2018. It also notes that the joint venture provides Moxian with a new revenue stream, giving it a percentage of Shewn’s sales processed through the Moxian+ UnionPay app.

Additionally, the joint venture is an effective way of having Moxian gain quicker entry into new markets within China at a lower price. Crystal Equity Research said that Moxian’s cash burn rate was only $1.3 million in the quarter ended June 2017 versus $5.4 million in the prior quarter. Shewn markets fine wines in China and plans to use Moxian’s relationship and app for payments through UnionPay. It is also planning to market its wines into luxury complexes through as many as 500,000 new specialized vending machines.

For more information, visit the company’s website at www.Moxian.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Monaker Group, Inc. (MKGI) CEO to Present at Robins Equity Research Roundup

Travel and technology company Monaker Group, Inc. (OTCQB: MKGI) this morning announced that it has been invited to present at the Third Annual Robins Equity Research Roundup, which is scheduled to take place September 26-27 at the Shilo Inn and Suites in Portland, Oregon. Monaker CEO Bill Kerby is scheduled to present on Tuesday, September 26 at 11:15 a.m. Pacific Time. He will be joined by Richard Marshall, the company’s director of corporate development, for one-on-one meetings with institutional analysts and investors on that same day. Kerby’s presentation is expected to focus on the Monaker Booking Engine (MBE), a new cloud-based technology platform that delivers ALR reservations that can be instantly confirmed. As the company noted in a news release earlier this month, the MBE platform is currently approaching its first commercial launch by a “major travel industry partner.”

To view the full press release, visit http://dtn.fm/I48iH

About Monaker Group

Monaker Group is a technology-driven travel company focused on delivering innovation to alternative lodging rentals (ALR) market. The Monaker Booking Engine (MBE) delivers instant booking of more than 1.4 million vacation rental homes, villas, chalets, apartments, condos, resort residences and castles. MBE offers travel distributors and agencies an industry-first: a customizable, instant-booking platform for alternative lodging. For more information, visit www.monakergroup.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Moxian, Inc. (NASDAQ: MOXC) O2O Commerce Marketplace Makes Mobile Payments Easier

• Provider of mobile payment tools
• Using social media to drive ecommerce
• Marketplace that links offline and online

A look at Nielsen’s latest Global Mobile Money Report (http://dtn.fm/C8SXf) shows that Moxian, Inc. (NASDAQ: MOXC) is in the right place at the right time. The Nielsen report shows that close to half of Chinese consumers are likely to use a mobile device to pay their bills in bars, restaurants and retail stores, a far, far higher number than in the U.S. or Europe. This revealing statistic, coupled with Moxian’s position at the nexus of online retail establishments and their brick-and-mortar counterparts, gives the tech company a bet on both ecommerce and traditional retailing. The company, based in mainland China, operates an online platform that uses the drawing power of social media to drive business to small and medium-sized enterprises (SMEs). Now, with its capability to handle mobile payments recently upgraded, Moxian is likely to see its bets on O2O commerce pay off handsomely in the near future.

Although, at present, global online sales are still only about 10 percent of overall retail sales, its trend has been ever upward. Moreover, that global average hides some eye-opening detail. While in North America and Western Europe online accounted for 7.7 percent and 8.2 percent of the overall retail market in 2016, respectively, the retail market in China is running at around 12 percent of total consumer sales, according to data reported by Deloitte (http://dtn.fm/2ldKN). In 2015, total retail sales of consumer goods in China were valued at $4.61 trillion, which puts online retail in China at around $553 billion, a mind-boggling level of exchange that surpasses the national income of 191 countries of the 211 recognized by the United Nations as sovereign states.

Already, many of these online transactions are being initiated through mobile devices, with some analysts estimating that, in China, mobile accounts for around three-quarters of all online payments. A study by the Financial Times, reported by NPR (http://dtn.fm/Q083n), says that the ‘Chinese spent $5.5 trillion through mobile payment platforms last year, about 50 times the amount in the U.S.’ So powerful is the trend to mobile in this country of 1.3 billion, some commentators are suggesting (http://dtn.fm/dSS9j) that ‘China… the first country in the world to use paper money… (may) be the first to stop. In Beijing it is hard to find a product or a service that cannot be purchased with a mobile.’

Moxian is cashing in on this cashless trend. In early 2017, the company announced the launch of a new version of its Moxian User App and Business App (New Version Apps) that feature built-in UnionPay payment modules. This follows the company’s strategic partnership with Beijing Chinaums, a subsidiary of China UnionPay, in December 2016.

This seamless integration of Moxian’s proprietary virtual currency engine and UnionPay’s powerful payment gateway will allow users (merchants and shoppers) of the New Version Apps to process payments through UnionPay’s payment gateway, which also supports payments from Alipay and WeChat Pay. The UnionPay payment gateway also meshes seamlessly with Moxian’s MO-Coin and MO-Point system, which rewards customers who use and process payments with the New Version Apps. The Moxian Software Machine also tracks customer behavior, which in turn allows Moxian to provide the participating merchants with complete and detailed analytic data and tools. Merchants on the Moxian Marketplace can study the behavior of their customers and respond with precise targeted marketing campaigns.

Moxian is out to make smartphone payments while shopping easier for the Chinese consumer, whether buying online or at a favorite bazaar. For the merchant, the company provides access to the latest, most sophisticated marketing tools. As China ditches cash, the Moxian O2O Marketplace looks set to continue blurring the line between offline and online commerce.

For more information, visit the company’s website at www.Moxian.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

India Globalization Capital, Inc. (NYSE: IGC) Reports Promising Progress of Cannabis-Based Alzheimer’s Drug Candidate

• IGC is the only publicly traded cannabis stock with patent filings for treating Alzheimer’s disease
• Company has a first-mover advantage in phytocannabinoid-based combination therapy
• Alzheimer’s is America’s most expensive disease, costing the country an estimated $259 billion in 2017

It is considered America’s most expensive disease, projected to cost an estimated $259 billion in the United States in 2017 and as much as $1.1 trillion by 2050 (http://dtn.fm/2UWLl). It is not cancer, and it is not AIDS. It is Alzheimer’s disease.

This devastating chronic neurodegenerative disease is the most common cause of dementia among older adults and is the sixth-leading cause of death in the U.S. There is currently no cure for Alzheimer’s disease, nor are there presently any effective treatments to slow the disease or reverse its effects, but India Globalization Capital, Inc. (NYSE MKT: IGC) is working to change that.

In a recent press release (http://dtn.fm/5qvM2), IGC discussed its progress on IGC-ADI, a drug candidate that is cannabis-based and targeted at lessening some of Alzheimer’s worst symptoms. IGC-ADI works through a molecular pathway that permits low doses of tetrahydrocannabinol (THC) to do five things:

Inhibit Aβ protein production
Inhibit Aβ protein aggregation
Reduce protein phosphorylation
Restore mitochondria function
Redirect the immune system
Amyloid beta peptide (Aβ) is a protein believed to cause the formation of plaque in the cerebral cortex and hippocampus, causing lesions. Alzheimer’s disease is believed to be caused by two different types of lesions—the first being senile plaque that is made up of amyloid beta peptides (Aβ plaque) and the second being neurofibrillary tangle, which is composed of highly phosphorylated Tau protein.

Aβ proteins are normally cleared away through biological processes, but, in Alzheimer’s patients, these proteins are unregulated and build up into insoluble fibroles. Senile plaques and extracellular misfolded oligomers resultantly form and are believed to be toxic to nerve cells in the brain. It has been found that IGC-AD1 may inhibit the production of amyloid beta peptide.

In a recent press release, IGC provided an update on in vitro data compiled from genetically engineered cell lines, which has been confirmed by IGC Senior Advisor Dr. Chuanhai Cao, who is also an associate professor of pharmaceutical sciences at the University of South Florida’s College of Pharmacy. The data shows that at varying THC concentrations, production of Aβ40 protein decreases by as much as 50 percent over a 48-hour time period.

Aβ40 and Aβ42 play a central role in amyloid plaques and have been implicated in the pathogenesis of Alzheimer’s disease. Dr. Cao’s studies at USF led to the filing of a patent by USF entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” IGC has since acquired the exclusive rights to the patent filing, and the company intends to advance the technology through medical trials, with the ultimate aim of bringing relief to Alzheimer’s sufferers.

IGC is currently the only publicly traded cannabis stock to have patent filings for a potential breakthrough Alzheimer’s treatment. This gives the company a first-mover advantage in phytocannabinoid-based combination therapy, as discussed in a recently published article featuring IGC and four other standout companies that are currently seeking to find viable treatments for Alzheimer’s (http://dtn.fm/9YfF0).

For more information, visit the company’s website at www.IGCInc.us

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Provides Update on Data Showing Effectiveness of THC in Addressing Underlying Cause of Alzheimer’s

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided an update on compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model. Per the update, the aggregation of Aβ protein in the cerebral cortex and hippocampus, which is believed to be a primary cause of Alzheimer’s disease, is decreased by as much as 40 percent when treated with varying concentrations of THC. “As Alzheimer’s progresses, synaptic dysfunction and the death of neurons lead to memory loss,” Ram Mukunda, CEO of IGC, stated in the news release. “These study results, when combined with the earlier reported data that shows IGC-AD1 reduces Aβ40 and Aβ42 production by as much as 50%, and 40%, without any toxicity, represent a highly significant novel breakthrough that could potentially bring much needed relief from this devastating disease.” Based on these findings, IGC intends to position IGC-AD1 as a drug that can be used both as a treatment for Alzheimer’s and as a prophylactic treatment for the prevention of Alzheimer’s. The company intends to commercialize a supplement version of IGC-AD1 to be sold as a medical dispensary product.

To view the full press release, visit http://dtn.fm/9qG5o

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Modifies JV Approach to Enter Strategic Markets in China

In an effort to expand more rapidly in China, Moxian, Inc. (NASDAQ: MOXC) has shifted the focus of its joint venture strategy, including the agreement with Shewn International Group of Shanghai. An excerpt of an article further discussing this topic reads: “Moxian, Inc. has changed its business strategy to grow more quickly within China, targeting the nation’s top four markets while also beginning to utilize a joint venture strategy in order to penetrate these markets more efficiently with the aid of entrenched businesses. MOXC’s marketing and sales team members are now acting as sales managers, working with independent agents to secure higher volume.”

To view the full article, visit: http://dtn.fm/M9PoR

About Moxian, Inc.

Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the company can be found at www.moxian.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

India Globalization Capital, Inc. (NYSE: IGC) Announces Alzheimer’s Drug Candidate Targeting Aβ Proteins

• More than 5.3 million people in the U.S. have Alzheimer’s disease, which has no effective cure or substantial treatment
• India Globalization Capital’s IGC-ADI drug candidate targets proteins associated with the buildup of lesions in the brain
• The company acquired exclusive rights to a patent, based on University of South Florida studies supporting THC’s role in inhibiting Aβ plaque production

Alzheimer’s disease now affects over 5.3 million people in the United States, imposing an estimated economic cost of $236 billion. There has been no effective treatment to slow down or reverse its effects. That may be about to change, as India Globalization Capital, Inc. (NYSE MKT: IGC) launched a press release (http://dtn.fm/w01OQ) detailing its work on a drug candidate, IGC-ADI, that targets the buildup of lesions in the brain associated with Alzheimer’s. Given that the number of cases is expected to double over the next two decades, a lack of a cure or other mitigating therapy is concerning. However, the company expects to soon begin trials that may yield promising new treatments.

The unconventional nature of this drug candidate is that it is tetrahydrocannabinol (THC)-based. Low doses of THC have been found to inhibit amyloid beta peptide (Aβ plaque) production. This protein is believed to cause plaque to form in the cerebral cortex and hippocampus. Phosphorylated Tau proteins make up another type of lesion, called a neurofibrillary tangle, that is also linked to AD. The Aβ proteins normally cleared away by biological processes are unregulated in Alzheimer’s patients, and therefore build up into insoluble fibroles. The result is the formation of senile plaques and extracellular misfolded oligomers that are thought to be toxic to nerve cells in the brain.

Now the only publicly traded pharmaceutical cannabis stock that addresses the disease, IGC has developed a drug that inhibits protein production and protein aggregation and reduces the phosphorylation of protein, as explained in the recent Brand Awareness Distribution article, “Alzheimer’s Disease: Cannabis Formulation Shows Promise”. The drug candidate IGC-ADI is believed to also have the potential to restore mitochondria function and redirect the immune system. Studies on genetically engineered cell lines conducted at the University of South Florida (USF) have provided supportive evidence for the company to move forward. At THC concentrations of 25nM, Aβ40 production was cut by 30 percent over a six-hour period, and by 35 percent over 24 hours. When doses of 2.5 μM were introduced, amyloid beta peptide production was reduced by the same level at six hours, 40 percent over 24 hours, and 55 percent over 48 hours (compared to 40 percent at lower THC concentrations).

The patent “THC as a Potential Therapeutic Agent for Alzheimer’s Disease,” was filed based on the findings of the USF studies conducted by Dr. Chuanhai Cao, an Associate Professor of Pharmaceutical Sciences at USF’s College of Pharmacy and an IGC Senior Advisor. Expected to conduct human medical trials, IGC has already acquired exclusive rights to the patent filing, allowing it to use and advance the technology to find potential treatments for Alzheimer’s patients.

IGC-ADI is one of six patents involving cannabis-based combination therapy, providing investors with opportunities to help support potentially revolutionary treatments for Alzheimer’s, epilepsy, Parkinson’s disease, depression and post-traumatic stress disorder.

For more information, visit the company’s website at www.IGCInc.us

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Provides Update on Data Linking THC to Decrease in Aβ40 Protein Production

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced compelling in vitro data compiled from genetically engineered cell lines showing that, at varying concentrations of THC, the production of Aβ40 protein decreases by as much as 50 percent over a 48-hour period. This is particularly noteworthy for patients with Alzheimer’s disease, as the condition often results in an imbalance of Aβ plaque that is believed to be toxic to nerve cells. This data, compiled by Dr. Chuanhai Cao, an IGC senior advisor and associate professor of pharmaceutical studies at USF’s College of Pharmacy, led to the filing of a patent by USF entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” In the news release, Ram Mukunda, CEO of IGC, stated, “IGC acquired the exclusive right to this patent filing and we plan to advance this technology through medical trials that can potentially bring much needed relief for patients suffering from AD.”

To view the full press release, visit http://dtn.fm/scAZ5

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Moxian, Inc. (NASDAQ: MOXC) Shifts to Joint Venture Strategy in Effort to Penetrate Key Markets in China

• Crystal Equity Research, encouraged by new joint venture strategy, forecasts rising revenue for Moxian (http://dtn.fm/Q8Fva)
• Key to market growth is UnionPay’s payment module in Moxian+ app
• MOXC now targets larger $2-4 million businesses for Moxian+ Merchant app sales

Moxian, Inc. (NASDAQ: MOXC) has changed its business strategy to grow more quickly within China, targeting the nation’s top four markets while also beginning to utilize a joint venture strategy in order to penetrate these markets more efficiently with the aid of entrenched businesses. MOXC’s marketing and sales team members are now acting as sales managers, working with independent agents to secure higher volume.

MOXC, an integrated platform operator focused on processing digital payments, is converting its unpaid platforms to paid platforms. Key to its new strategy is MOXC’s relationship with China’s dominant payment processor, UnionPay. A UnionPay processing module on the Moxian+ platform is critical in allowing MOXC to attract new joint venture partners in China and neighboring Asian markets. Now, the Moxian+ Merchant platform offers digital processing modules for UnionPay, Alipay, and WeChatPay.

“We anticipate revising our revenue estimates upward when Moxian confirms the formalization of the joint venture with Shewn International,” the Crystal Equity Research report said. It now projects MOXC revenues at $2.3 million by FY2018.

Crystal Equity Research sees the joint ventures as strengthening and making more efficient Moxian’s plans to penetrate the markets of Beijing, Shanghai, Shenzhen, and Guangzhou. “We view it as an important catalyst for valuation,” the report said. It added that such joint ventures could raise investor confidence in the company and result in higher valuation of shares.

The joint venture with Shewn International Group of Shanghai gives MOXC a new revenue stream from a percentage earned on all its processing of payments from Shewn. Further, Crystal Equity Research notes that MOXC is burning less cash with the new joint venture strategy. It noted that the company used only $1.3 million in cash during the quarter ended June 2017 versus the $5.4 million the company spent in the prior quarter. The reduction was attributed to reduced selling, general and administrative (SG&A) costs with the new tactics.

Shewn International, in addition to its fine wine sales in wine clubs, also plans to open as many as 500,000 new vending machines across China to sell its fine wines. Affluent residents of luxury apartment complexes, Shewn believes, will react positively to the convenience of buying its upscale wines, offered at the correct temperature and humidity, from these machines.

For more information, visit the company’s website at www.Moxian.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Monaker Group, Inc. (MKGI) Divests Non-Core Assets, Eliminates Convertible Debt ahead of Nasdaq Application

Travel and technology company Monaker Group, Inc. (OTCQB: MKGI) this morning announced that it has divested certain non-core assets for total consideration of $2.9 million. Additionally, the company has completed the conversion of $1.4 million of convertible debt owned by a long-term shareholder and company insider, eliminating the remainder of its convertible debt in preparation for a planned up-listing. “The divestiture of these non-core assets and elimination of convertible debt, along with our recently completed $3 million private placement, substantially strengthens our balance sheet as we prepare our application for up-listing on the Nasdaq Capital Market,” Bill Kerby, CEO of Monaker Group, stated in the news release. “The private placement and conversion of debt into equity reflects the confidence of our major stakeholders in our business model and near-term growth prospects.” The planned up-listing comes as Monaker Group nears the first commercial launch of its cloud-based Monaker Booking Engine (MBE) by a major travel industry partner. The company’s management believes that completion of this milestone, as well as the added exposure provided by a Nasdaq listing, will help attract “a broader base of global institutional and retail investors, and provide greater liquidity for [its] shareholders.”

To view the full press release, visit http://dtn.fm/iuVO2

About Monaker

Monaker Group is a technology-driven travel company focused on delivering innovation to alternative lodging rentals (ALR) market. The Monaker Booking Engine (MBE) delivers instant booking of more than 1.2 million vacation rental homes, villas, chalets, apartments, condos and castles. MBE offers travel distributors and agencies an industry-first: a customizable instant booking platform for ALR. Monaker’s NextTrip.com B2C website, also powered by MBE, is the first to offer significant instantly-bookable ALR products along with mainstream travel products and services all on a single site. NextTrip also features rich content, imagery and high-quality video to enhance a traveler’s booking experience and assist in the search, decision and buying process for both individuals and groups. For more information, visit www.monakergroup.com or www.nexttrip.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Net Element (NASDAQ: NETE) and the Growing Value of the Payments Processing Business

• Non-bank payment processing at $1.2 trillion, with 12.8% CAGR forecast through 2021
• Large bank takeovers already underway
• NETE operating the right business in the right sector at the right time

Savvy investors always look to capitalize on hot sectors of the market and often single out potential winners in such uptrend niches. Short-term traders and long-term investors alike seek out stocks in sectors on the upswing and aim to position themselves prior to large upside moves. Though it may be perceived as mundane, payment processing is proving to be a just hot growth sector grabbing global investor attention.

A recent article published by MarketWatch (http://dtn.fm/0mPnD) clarified the opportunity. Preliminary takeover approaches from J.P. Morgan Chase & Co. (NYSE: JPM) spurred frenzied interest in payment processor Worldpay Group PLC (OTC: WPYGY) and rapidly drove its stock to new highs. More importantly, this activity highlighted the growing value of the payments processing business.

In the MarketWatch piece, Ken Odeluga, a market analyst at City Index, stated, “Interest by the U.S.’s largest bank, J.P. Morgan, points to an identification of digital-payment processing as one of highest potential spheres of remaining growth in financial services, particularly if we assume that retail banking in Western markets is near saturation point.”

This becomes even more apparent when realizing that total digital payment transactions outside of conventional providers like banks are projected to be worth roughly $740 billion this year and are expected to increase at a compound annual growth rate of 12.8% through 2021, exceeding $1.2 trillion by the end of the period.

Net Element, Inc. (NASDAQ: NETE), a technology-driven mobile payments and transactional services company, is perfectly positioned is this explosive sector and poised to capitalize on this growth curve. Net Element provides turn-key services, including the technology and services required for cashless transactions, to small- and medium-sized businesses throughout the United States and in select international markets. The company’s products and services include mobile payments, value-added services, marketing solutions and business analytics. Through its wholly-owned group of companies, Net Element’s global divisions support electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices.

The South Florida Business Journal recognized Net Element as one of the fastest growing technology companies in the United States last year, and, in 2012, the company’s Unified Payments division was named the fastest-growing private company in America by Inc. magazine. Already exhibiting strong domestic growth, the company added a record number of merchants to its customer base in Q1 2017, and Net Element is simultaneously launching expanded international efforts. With significant footprints already established in select international markets, Net Element expects to broaden its global presence by leveraging its omni-channel platform into targeted emerging markets.

At first blush, payment processing doesn’t seem like an exciting investment opportunity, but don’t try to convince the shareholders of Worldpay, who just enjoyed a 33% surge in share price. Payment processing is proving to be one of the highest potential spheres of growth in the financial services arena. As the value becomes more recognized, it’s easy to envision Net Element as the next beneficiary of this growth and a subsequent surge in value.

For more information, visit the company’s website at www.NetElement.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – India Globalization Capital (NYSE: IGC) a Dark Horse in the Race to Treat Alzheimer’s

Alzheimer’s is the most expensive disease in the United States, and pharmaceutical companies are racing to find viable treatments for this devastating disease, which currently affects more than 5.3 million Americans and their loved ones. Wall Street is placing bets on who will win the race to treat Alzheimer’s, and India Globalization Capital (NYSE MKT: IGC) is one promising candidate with a compelling patent-pending treatment protocol. An excerpt from an article further discussing this reads: “IGC is a pioneer in the development of new classes of phytocannabinoid pharmaceuticals with broad therapeutic applications for both humans and animals. IGC’s pipeline of patented and patent pending therapeutics includes treatments for pain, post-traumatic stress disorder, cachexia, neurologic disorders, Parkinson’s, and, now, Alzheimer’s disease. IGC recently acquired the exclusive rights to its novel THC-based treatment for Alzheimer’s disease from the University of South Florida (http://www.igcinc.us/alzheimers-disease/). The patent identifies discovery of a new pathway in which low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is exactly what occurs in Alzheimer’s disease and causes cognitive decline.”

To view the full article, visit http://dtn.fm/Orm8S

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in humans, dogs and cats. In support of this effort, IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html